Invasive Candidiasis Management in Critical Care

Invasive candidiasis represents a spectrum of life-threatening fungal infections that commonly afflict critically ill patients. It encompasses candidemia—bloodstream invasion by Candida species—and deep-seated infections such as intra-abdominal candidiasis. Intensive care unit (ICU) patients are predisposed by prolonged central venous access, broad-spectrum antibiotic exposure, total parenteral nutrition and impaired immune function. Early identification is challenging owing to the low sensitivity of culture-based diagnostics and the non-specific nature of clinical signs. Consequently, management hinges on a combination of prompt empirical or pre-emptive antifungal therapy, source control measures such as drainage of infected collections, and removal of colonised devices. Advances in non-culture diagnostics, notably serum and peritoneal β-D-glucan assays and molecular detection of Candida DNA, have enhanced the timeliness of antifungal initiation and supported stewardship efforts aimed at minimising unnecessary drug exposure. Echinocandins remain first-line agents for most presentations, with de-escalation to azoles guided by microbiological results and patient stability. Optimal outcomes rely on multidisciplinary collaboration, integration of novel biomarkers into clinical algorithms and adherence to antifungal stewardship principles to curb resistance and reduce healthcare burden.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Invasive Candidiasis Management in Critical Care publication trend

The graph below shows the total number of articles in invasive candidiasis management in critical care across all publications each year (not limited to Nature Index journals).

Technical terms

Invasive candidiasis: Severe infection caused by Candida species that invades the bloodstream or deep tissues.

Intra-abdominal candidiasis: Candida infection confined to the peritoneal cavity, commonly presenting as abscesses or secondary peritonitis.

Candidemia: The presence of Candida species in the bloodstream, often leading to systemic complications.

β-D-glucan assay: A non-culture diagnostic test that detects a fungal cell-wall component in blood or other body fluids to suggest invasive infection.

Empirical antifungal therapy: The initiation of antifungal treatment based on clinical suspicion and risk factors, prior to definitive microbiological confirmation.

References

1. Combination of serum and peritoneal 1.3-beta-d-glucan can rule out intra-abdominal candidiasis in surgical critically ill patients: a multicenter prospective study. Critical Care (2023).
2. Lower (1,3)-beta-d-glucan sensitivity and in vitro levels in Candida auris and Candida parapsilosis strains. Clinical Microbiology and Infection (2024).
3. Empirical antifungal therapy for health care-associated intra-abdominal infection: a retrospective, multicentre and comparative study. Annals of Intensive Care (2024).